NxStage Medical Inc. is a medical technology company that develops, manufactures and markets innovative products and services for patients suffering from chronic or acute kidney failure. We also operate a small number of NxStage Kidney Care dialysis centers, independently and in some instances as joint ventures, that treat end-stage renal disease (ESRD) patients directly. Our primary product, the System One, was designed to satisfy an unmet clinical need for a system capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes, as well as more traditional care settings such as hospitals and dialysis centers. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies that are more practical to deliver in the home setting including more frequent hemodialysis and nocturnal hemodialysis. Clinical literature suggests that more frequent hemodialysis represents a clinically significant innovation in care delivery for patients with ESRD, and it has been reported to deliver important clinical benefits and improved quality of life for certain patients. In addition to the System One, we sell blood tubing sets and needles to dialysis clinics and hospitals for use with traditional dialysis machines.
Company profile
Website
CEO
Jeffrey H. Burbank
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
IRS number
43454702
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
24 Apr 20
CT ORDER
Confidential treatment order
31 Dec 19
CT ORDER
Confidential treatment order
31 Dec 19
CT ORDER
Confidential treatment order
31 Dec 19
CT ORDER
Confidential treatment order
31 Dec 19
CT ORDER
Confidential treatment order
3 Oct 19
CT ORDER
Confidential treatment order
5 Jun 19
15-12G
Securities registration termination
5 Mar 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Feb 19
Latest ownership filings
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|